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ABSTRACT  
Objective: The aim of the present study is to prepare and evaluate a co-processed excipient from commercially available Avecil PH102 and silicon 
dioxide colloidal (SDC) using direct compression technique for preparation of tablets.  
Methods: The effect of the ratio of the two components on the properties of the prepared co-processed excipient has been investigated. In addition, 
it was evaluated for flowability, compressibility, and compatibility utilizing Fourier transforms Infrared (FTIR) and Differential scanning 
calorimetry (DSC) analysis. Tablets were produced by direct compression utilizing the co-processed additive with diazepam or atorvastatin calcium 
as model drugs in addition to magnesium stearate and talc as a lubricant. The addition of super disintegrant croscarmellose sodium or tablets 
preparation by wet granulation was utilized for comparison regarding the properties of prepared tablets. The prepared tablets were characterized 
for the drug content, hardness, friability, disintegration, dissolution, and stability.  
Results: Optimal physicochemical properties of the excipient from a manufacturing perspective were obtained using a co-processed Avecil PH102-
with SDC (2% w/w) to get a mixture. The FTIR and DSC analysis showed no chemical interaction. The properties of tablets made using co-processed 
excipient showed good hardness, friability, acceptable tablet disintegration time, dissolution rate, and stability comparable to that obtained by the 
multistep method of wet granulation. Although the addition of super disintegrant more shorten the disintegration time but the obtained value 
without croscarmellose sodium is still satisfied the requirement.  
Conclusion: The Avecil PH102-SDC co-processed excipient produced was found to be promising as a valuable industrial, pharmaceutical excipient 
for the production of compressed tablets with good physical properties and fast dissolution.  
Keywords: Low-cost excipient, Direct compressible, In situ prepared additives. 
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INTRODUCTION 
Tablets and capsules are until yet a preferable oral dosage forms 
comparison to others because they provide accurate dose and high 
patient compliance, their large scale manufacturing is easy and 
economic [1]. The continuous researches in the last years for 
improving the properties of main components of tablets including 
the active ingredient and additives in addition to tablet machines 
retain the tablets as most desirable dosage form [2]. 
Although publications about direct compression are limited, but the 
lower number of steps and cheap procedure of direct compression 
in comparison to granulation method in addition to the production 
of new or modified additives move the focusing on this method and 
its components [3]. 
Co-processing is one of the approaches to improve the 
characteristics of additives the easiest and simplest method to 
modify the properties of two excipients to produce a new one with 
better quality for utilizing in direct compression of tablets [4, 5]. The 
compatibility and ratio of two excipients in the preparation of new 
co-processed excipient are of great importance in the determination 
of final properties of the new additive. 
Since the co-processing is a physical change with no chemical 
intervention, thus it is more desirable than other approaches [6]. 
The aim of this work is in situ preparation of co-processed additive 
of low cost, good compressibility, uniform distribution, and simple in 
preparation in order to be a direct compression excipient alternative 
to the high-cost readymade excipient available in the market that 
used by many drug factories. Two model drugs, diazepam and 
atorvastatin calcium, belong to biopharmaceutical class I and II 
respectively were selected to incorporate in the tablets prepared 
using the new excipient to evaluate the application of excipient using 
the drug of different biopharmaceutical properties. 
MATERIALS AND METHODS 
Materials 
Atorvastatin calcium and pure diazepam powder were supplied by 
Al-furat pharm industry, Iraq. Avecil PH102, SDC, and 
Croscarmellose sodium were supplied by Samara Drug Industries 
(SDI), Iraq. Talc and Mg stearate were obtained from BDH, England. 
All other materials utilized in the research were of pharmaceutical 
grade 
Methods 
Preparation of Co-processed avecil PH102-SDC 
Four co-processed mixtures of Avecil PH102 and SDC at different 
SDC percent (1, 1.5, 2, and 2.5% w/w) were prepared.  
The components of each mixture were sieved through 25 mesh No 
sieve, after that all components for 5 min mixed at 10 rpm utilizing a 
conical mixer machine (Erweka, Germany).  
The mixture then was moistening with sufficient amount of water to 
achieve wet mass. After 15 min, through 60 mesh No sieve the wet 
mass was passed, and then dried for one hour at 50 °C. 
Evaluation of the prepared Co-processed excipient  
Angle of repose  
Following the funnel method, the angle of repose of the prepared co-
process powder mixture was determined. A funnel was stood over 
flat surface in a distance of 3 cm. The mixture was gradually poured 
through the funnel until the apex of the conical pile so formed just 
touched the tip of the funnel. The tangent of the angle was calculated 
using the following equation after measuring the radius and the 
height of the cone of the powders [7]. 
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Where θ is the angle of repose, h is the powder height, r is the 
powder radius. The standard values and their interpretation 
according to USP are shown in the table (1). 
Compressibility (Carr’s) index  
An accurate weight of prepared co-process product mixture was 
poured into a graduated cylinder to measure volume initially (V◦) 
and then tapping was done until a constant volume was reached (Vf). 
The standard values and their interpretation according to USP are 
shown in table (2). The Carr's index was calculated using the 





Fourier transform infrared (FTIR) spectroscopy  
The Fourier transform infrared spectroscopy (FTIR) spectra were 
obtained using FTIR Shimadzu, Japan. Samples of a physical mixture of 
Avecil PH102 with SDC and optimum prepared co-process powder 
mixture were compressed with potassium bromide separately. The 
spectrum obtained was in range wave number of 4000-400 cm-1 [9].  
Differential scanning calorimetry (DSC) 
DSC can be used to determine the compatibility between drugs with 
an excipient and also used between two excipients. Thermal 
characteristics of samples of Avecil PH102, SDC, and optimum 
prepared co-process were determined by an automatic thermal 
analyzer system (Shimadzu DSC–60, Japan). Accurately weighed 
samples (2 mg) were placed in none hermetically aluminium pans 
and heated at the rate of 20 ˚C/minute against an empty aluminium 
pan as a reference covering a temperature range of 50 ˚C to 200 ˚C. 
Preparation of tablets of model drugs 
Table 3 shows the composition of tablets prepared using model drug 
either atorvastatin calcium or diazepam. All formulas prepared by 
direct compression method except formulas F4 and F7. The all 
components of formula except the lubricant were accurately 
weighed and passed through 60 mesh sieve. The powder was 
blended in a poly bag by tumbling for 15 min. The blending was 
continuing for further 1 minute after addition of magnesium stearate 
and talc as a lubricant. The mixture of powder was compressed using a 
9-mm single punch tablet machine (TDP-6, China). 
The tablets of formulas F4 and F7 were prepared by wet granulation 
method. The drug and other ingredients were mixed together except 
the lubricant, and then a specified volume of an ethanolic solution of 
Polyvinylpyrrolidone (PVP) (10% w/v) was added and mixed to 
form wet mass. The wet mass was granulated using sieve no. 10 and 
dried in a tray dryer at 65 °C for 10 min, and then re-granulated 
through sieve no. 60. The dried granules were then blended a poly 
bag with magnesium stearate and talc as lubricant for 1 minute and 
then compressed into tablets. 
 
Table 1: The determination of flow properties in term of angle of repose 




˃40 Very poor 
 
Table 2: Determination of flowability according to percent of compressibility 
Flowability % of compressibility 
Excellent 5-12 
Good 12-16 
Fair passable 18-21 
Poor 23-35 
Very poor 33-38 
Very very poor ˃40 
 
Table 3: Composition of tablets prepared to investigate the application of co-processed excipient 
Ingredients (mg) Formulas No. 















Active ingredient 20 20 20 20 2 2 2 
Prepared Excipient  170  165  122   
Lactose  170  166  122 120 
Croscaremellose 
sodium 
  5     
PVP    4   2 
Talc 8 8 8 8 4 4 4 
Mg stearate  2 2 2 2 2 2 2 
Total weight 200 200 200 200 130 130 130 
Note: Formulas with star means prepared by wet granulation method 
 
Evaluation of the prepared model drugs tablets 
Weight variation 
Randomly, twenty tablets were selected after compression and the 
mean weight was determined. None of the tablets should deviate 
from the average weight by more than±7.5%. 
Uniformity of content  
The content of diazepam was determined by High-pressure liquid 
chromatography (HPLC) method. Chromatography analysis was 
performed by Knauer HPLC system; the isocratic mobile phase 
consisted of buffer pH 3.4: Acetonitrile in the ratio of 55:45v/v at a 
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flow rate of 1.0 ml/min through C18 column (ODS, 25 cm ×4.6 mm, 
5μ) was used as stationery phase. The detection wavelength for 
diazepam is 250 nm. Diazepam peak appeared at 5.65 min (fig. 1).  
By appropriate aliquots of the standard diazepam solutions with the 
mobile phase, eight working solutions ranging between 10-80 μg/ml 
for diazepam were prepared. Each experiment was performed in 
triplicate according to optimized chromatographic conditions. The 
peak areas of the chromatograms were plotted against the 
concentration of diazepam to obtain the calibration curve with high 
correlation as shown in fig. (2) [10]. 
For determination of diazepam content in prepared tablets, twenty 
tablets were weighed, powdered and calculated the average 
weight of each tablet. Then the weight equivalent to 1 tablet was 
transferred into a 100 ml volumetric flask, 80 ml of diluent 
(mobile phase) added and sonicated for 25 min, further, the 
volume made up with diluents and inject the filtrate into HPLC 
system.  
The content of Atorvastatin Calcium was determined by HPLC 
method. Chromatography was performed with Knauer HPLC system; 
the isocratic mobile phase consisted of Acetonitrile: 0.01M 
potassium dihydrogen phosphate solution in the ratio of 40:60 v/v 
adjusted to pH 4.0 with phosphoric acid at a flow rate of 1.0 ml/min 
through C18 column (ODS, 25 cm ×4.6 mm, 5μ) was used as 
stationary phase. The detection wavelength for the drug is 240 nm. 
Atorvastatin Calcium peak appeared at 6.39 min (fig. 3). By 
appropriate aliquots of the standard Atorvastatin Calcium solutions 
with the mobile phase, nine working solutions ranging between 0.1-
0.9 μg/ml for Atorvastatin calcium were prepared. Each experiment 
was performed in triplicate according to optimized chromatographic 
conditions. 
The peak areas of the chromatograms were plotted against the 
concentration of Atorvastatin calcium to obtain the calibration curve 
with high correlation as shown in fig. (4)[11]. 
For determination of Atorvastatin calcium content in prepared tablets, 
twenty tablets of Atorvastatin were accurately weighed and finely 
powdered. A portion of powder, equivalent to the weight of one tablet, 
was accurately weighed and transferred into 20 ml volumetric flask 
and 8 ml of mobile phase was added to it. 
 
Fig. 1: HPLC chromatogram of pure diazepam 
 
 
Fig. 2: Calibration curve of diazepam using HPLC method 
 
The volumetric flask was sonicated for 20 min until there was 
complete dissolution of the atorvastatin. The solution was made 
up to mark with mobile phase and then filtered through a 0.45 µm 




Fig. 3: HPLC chromatogram of pure atorvastatin calcium 
 
 
Fig. 4: Calibration curve of atorvastatin calcium using HPLC method 
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The crushing strength of the tablets was measured using a Monsanto 
hardness tester. Three tablets from each formulation batch were 
tested randomly and the average reading±SD was recorded. 
Friability  
Twenty tablets were weighed and placed in a Roche friability tester 
and the equipment was rotated at 25 rpm for 4 min. The tablets 
were taken out, dedusted and reweighed. The percentage friability 
of the tablets was calculated using the following equation [12]. 
Percent friability = 
initial weightfinal weight
initial weight
 X 100 
In vitro disintegration time 
Disintegration time (DT) of the model drug tablets were measured 
using a six station disintegration test apparatus (Disintegration 
Tester-USP, Electrolab, India) with disc according to the guidelines 
of British Pharmacopoeia. Distilled water 
at 37±2 °C temperature was used as the disintegration medium. Six 
tablets of each brand were tested and the average disintegration 
time was calculated [13].  
Dissolution studies  
In vitro dissolution study of Atorvastatin Calcium was performed by 
using type II (paddle) dissolution apparatus (Copley, UK) at 80 rpm, 
and 900 ml of 0.1N HCL was used as dissolution medium. Six tablets 
of each formula were tested, one tablet in each of six vessels of the 
dissolution apparatus. The temperature of dissolution medium was 
maintained at 37±0.5 °C. Five ml aliquot of the dissolution medium 
was withdrawn at 45 min. Analysis of filtered solution was 
measured by HPLC method described in the section of 
determination of Atorvastatin calcium in tablets.  
Dissolution of diazepam from prepared tablets was evaluated 
according to United States Pharmacopeia (USP) apparatus I using 
900 ml of 0.1N HCL as a medium at 37 °C and 80 rpm. Six tablets of 
each formula were tested, one tablet in each of six vessels of the 
dissolution apparatus. Aliquot (5 ml) was withdrawn at 30 min. The 
sample filtered with 0.45 µm membrane filter, mixed with an equal 
volume of the mobile phase, and analyzed by the mentioned HPLC 
method [14]. 
Stability studies  
Stability study was carried out on optimized formula. The tablets 
were stored at 40±2 °C/75±5 % RH for one year, and then the samples 
were evaluated for drug content by HPLC at the end of the study.  
Statistical analysis 
The mean±standard deviations of the experiments were calculated 
in addition to paired t-test was used in analysis at a significance 
level of p ≤ 0.05.  
RESULTS AND DISCUSSION 
Directly compressible excipient can be prepared by many methods, 
one of them is the Co-processing. Co-processing of excipients could 
lead to the production of excipients with better properties than the 
pure individual excipient or the physical mixture of their 
components. Avecil PH102-SDC co-processed excipient was 
prepared at different mixing ratios of SDC relative to Avecil PH102. 
The results of flow properties of various batches of co-processed 
excipients at different mixing ratios are shown in table 4.  
The results show that the angle of repose and Carr’s index (CI) 
decreased significantly (p<0.05) as the content of SDC in the co-
processed excipients increased until the optimum properties with 
2% w/w SDC, above this percent there is no significant (p>0.05) 
improvement in flow properties. Although all batches of co-
process excipient showed better flow properties than pure Avecil 
PH102, but co-processed excipient contains 2% w/w SDC consider 
the best among all batches of co-process excipients since it is 
showed excellent flowability according to pharmacopeia 
specification [15]. 
 
Table 4: The physical properties of different prepared co-process 
Products Average angle degree of Repose (°) Compressibility Index (%) 
Pure Avecil PH102 powder 31.5±0.7 33.0±0.90 
Excipient contains 1.0% CSD 30.5±0.2 32.0±0.50 
Excipient contains 1.5% CSD 29.0±0.4 28.0±0.30 
Excipient contains 2.0% CSD 28.0±0.4 15.0±0.04 
Excipient contains 2.5% CSD 28.0±0.3 14.7±0.03 
 
Analysis of a physical mixture of Avicel PH102 with SDC by FTIR 
(Shimadzu FTIR 8000, Japan) shows a combination of 
characteristic peaks of both including peaks at 806.49, 1180.35, 
1647.26, 2365.76, 3356.78 cm-1which belong to Avicel PH102 
while remaining peaks belong to the SDC as shown in fig. (5) and 
these results are in good agreement with that obtained by Chella 
Naveen et al. [16]. The appearance of main peaks in the physical 
mixture and optimum coprocessed excipients formulation as 
shown in fig. (6) Indicate the absence of chemical interaction 
between the two excipients. 
 
 
Fig. 5: FTIR spectrum of physical mixture of avecil PH102 with SDC 
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Fig. 6: FTIR spectrum of optimum prepared co-process excipient 
 
The DSC thermogram of Avicel PH102 exhibited a broad 
endothermic peak at 80.70 °C that might correspond to the 
volatilization of adsorbed water as shown in fig. (7)[17]. The thermal 
behavior of SDC did not show any sharp peaks, revealing that this 
material was almost in an amorphous state as shown in fig. (8) [18].  
The DSC thermogram of optimum co-processed excipients shown in 
fig. (9) Revealed a broad peak at 64.64ᵒC differ than thermograms of 
pure excipients  indicating that co-processed excipients technique led 
to the formation of new excipient with developed physical properties 
and this observation also recorded by Sanjay SP et al. [19]. 
 
 
Fig. 7: DSC thermogram of pure avicel PH102 
 
 
Fig. 8: DSC thermogram of pure SDC 
Ghareeb et al. 




Fig. 9: DSC thermogram of optimum prepared co-process excipient 
 
Analysis of evaluation parameters of prepared tablets as shown in 
table (5) indicates that co-processed incorporated tablet prepared 
by direct compression (F1 and F5) revealed better  
properties than that used lactose as excipient (F2 and F6) utilizing 
Atorvastatin calcium and diazepam as model drugs respectively, 
especially regarding high hardness, fast disintegration and dissolution.
  
Table 5: The evaluation parameters of the prepared tablets of model drugs 
Formula  F1 F2 F3 F4 F5 F6 F7 
Hardness (kg/cm²) 6.5 2.6 5 6.5 6 2.7 7.5 
±0.02 ±0.007 ±0.03 ±0.03 ±0.05 ±0.01 ±0.04 
Friability (%) 0.3 1.2 0.25 0.8 0.11 1.4 0.85 
±0.004 ±0.002 ±0.004 ±0.003 ±0.001 ±0.003 ±0.004 
Disintegration time (sec) 60 55 30 360 40 38 420±0.3 
±0.9 ±0.7 ±0.2 ±1.3 ±0.7 ±0.4 
Percent dissolved  95 98 97 78 98 99 85 
at specified time ±2.4 ±1.7 ±1.2 ±3.2 ±1.3 ±1.5 ±1.6 
Drug content (%) 100 99 100 97 100 98 95 
±1.9 ±1.3 ±1.8 ±1.2 ±1.1 ±1.5 ±1.9 
Note: All values are mean of triplicate experiments±SD 
 
In addition, comparable results were obtained relative to that tablets 
prepared by multistep wet granulation method (F4 and F7). 
Although the addition of super disintegrant in formula (F3) shows 
more enhancement in disintegration time, but still the impact of use 
the prepared co-processed excipients is significant and enough for 
good tablets properties requirements.  
Stability study that carried out on optimized formulas (F1 and F5) 
indicates that there is no significant (p<0.05) changes in all 
properties of prepared tablets utilized the co processed excipients.  
CONCLUSION 
This work indicates that we can prepare the direct compression 
(DC) excipients immediately during the preparation of tablets batch 
without the need for commercial DC excipients of the high cost. In 
addition, the physical and chemical properties of manufactured 
tablets using the prepared excipients are of good performance 
with significant improvement in dissolution percent and stability 
of drug. 
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